Cytiva Launches Next-Generation Biacore 8 Series Systems to Accelerate Drug Discovery Workflows

22 May 2026 | Friday | News

New Biacore 8S and Biacore 8S+ systems combine ultra-fast SPR screening with high-quality molecular characterization, while Biacore Insight Software v7.0 introduces objective Sensorgram comparison for advanced comparability analysis

  • New Biacore 8S and Biacore 8S+ systems combine rapid screening and high-quality molecular characterization in a single system
  • Biacore Insight Software v7.0 adds Sensorgram comparison for objective similarity scoring
 
Cytiva, a Danaher company and a leader in the life sciences industry, is introducing the next generation of its Biacore 8 series SPR systems, enabling scientists to generate reliable interaction data faster, as drug discovery grows more complex. The new Biacore 8S and Biacore 8S+ systems bring together rapid screening and high-quality molecular characterization in a single system, reducing hands-on time through integrated plate handling, automated workflows, and extended unattended operation, without compromising data quality.
 
Tim Bervoets, President, Discovery & Medical, Cytiva, says: “Scientists are being asked to move faster while working with increasingly complex molecules and tighter resources. The next generation of Biacore 8 series systems is designed to help teams focus their time and investment on the most promising candidates by delivering confident interaction data earlier in the discovery process.”
 
The systems can screen 384 proteins in approximately 15 minutes, 16 times faster than the previous generation. This allows scientists to scale screening activities, while further improving the ability to resolve the most challenging interactions in late-stage characterization.
 
As part of this update, Cytiva is also advancing its Biacore Insight Software v7.0 with Sensorgram comparison, a feature that converts full interaction profiles into an objective similarity score. This gives scientists a clearer way to assess comparability against a reference sample and supports applications such as biosimilar comparability, batch-to-batch monitoring, and assessing the impact of process and formulation changes. It also supports outputs aligned with comparative analytical assessment and 21 CFR Part 11 compliance.
 
The Biacore 8S and Biacore 8S+ systems and the Biacore Insight Software v7.0 will be available to order in the summer of 2026.

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close